Real-World Evaluation Of First-Line (1l) Pembrolizumab (Pembro) Monotherapy For Pd-L1-Positive (Tps >= 50%), Advanced Nsclc In JapanY. Goto, M. L. Santorelli,K. Taniguchi,T. Kamitani, M. Irisawa, K. Kanda,M. Abe,T. Burke, H. NokiharaANNALS OF ONCOLOGY(2021)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要